Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

PURPOSE: We sought to compare the economic impact of treatment-related adverse events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or second-line (FL or SL) therapy in the US. METHODS: We used healthcare claims data fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Ryan N, Ramsey, Scott D, Lalla, Deepa, Masaquel, Anthony, Kamath, Tripthi, Brammer, Melissa, Hurvitz, Sara A, Sullivan, Sean D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047276/
https://www.ncbi.nlm.nih.gov/pubmed/24926422
http://dx.doi.org/10.1186/2193-1801-3-259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047276/
https://www.ncbi.nlm.nih.gov/pubmed/24926422
http://dx.doi.org/10.1186/2193-1801-3-259

Ejemplares similares